ABSTRACT
Background To make progress towards malaria elimination, a highly effective vaccine targeting Plasmodium vivax is urgently needed. Evaluating the kinetics of natural antibody responses to vaccine candidate antigens after acute vivax malaria can inform the design of serological markers of exposure and vaccines.
Methodology/Principal Findings The responses of IgG antibodies to 9 P. vivax vaccine candidate antigens were evaluated in longitudinal serum samples from Brazilian individuals collected at the time of acute vivax malaria and 30, 60, and 180 days afterwards. Antigen-specific IgG correlations, seroprevalence, and half-lives were determined for each antigen using the longitudinal data. Antibody reactivity against Pv41 and PVX_081550 strongly correlated within each of the four time points. The analysis identified robust responses in terms of magnitude and seroprevalence against Pv41 and PvGAMA at 30 and 60 days. Among the 8 P. vivax antigens demonstrating >50% seropositivity across all individuals, antibodies specific to PVX_081550 had the longest half-life 100 days (95% CI, 83—130 days), followed by PvRBP2b (91 days; 95% CI, 76—110 days) and Pv12 (82 days; 95% CI, 64—110 days).
Conclusion/Significance This study provides an in-depth assessment of the kinetics of antibody responses to key vaccine candidate antigens in Brazilians with acute vivax malaria. Follow-up studies are needed to determine whether the longer-lived antibody responses induced by natural infection are effective in controlling blood-stage infection and mediating clinical protection.
AUTHOR SUMMARY To successfully eliminate malaria, highly effective vaccines against the two major human malaria species, Plasmodium falciparum and Plasmodium vivax, will be needed. Vaccines against the blood form of malaria generate antibodies that target specific proteins on the Plasmodium parasite to reduce its replication within the host. Studying the antibody response after natural malaria infection can help identify blood markers of parasite exposure and also shed light on the magnitude and longevity of antibodies to vaccine candidate proteins. We performed a study to determine the frequency, magnitude, and longevity of natural antibody responses against nine P. vivax vaccine candidate proteins in patients with vivax malaria in Brazil. These proteins were selected based on prior studies demonstrating that antibodies against these proteins were either associated with protection against vivax malaria or have been tested as blood markers of recent infection with vivax malaria. We identify specific vivax proteins that produce more frequent and longer-lived antibody responses in this population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was funded with support from the Indiana Clinical and Translational Sciences Institute funded, in part by Grant Number UL1TR002529 from the National Institutes of Health (NIH), National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award. T.M.T was supported by NIH K08AI125682. Additional support was provided by NIH R01 AI137154 (J.C.R). W.H.T. is a Howard Hughes Medical Institute-Wellcome Trust International Research Scholar (208693/Z/17/Z) and supported by National Health and Medical Research Council of Australia (NHMRC) (GNT1160042, GNT1154937). R.J.L. and I.M. are also supported by the NHMRC (GNT1173210 to R.J.L., GNT1092789, GNT1134989, GNT1132975 and GNT1043345 to I.M.). The original field study was supported by Fundação de Amparo à Pesquisa de Minas Gerais (FAPEMIG, APQ-00769-12) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq: 470315/2012-1). R.N.R.S. was recipient of CAPES doctoral fellowship. Q.Q.H. acknowledges funding from the NIH (R01GM111639, R01GM115844) and the Michael J. Fox Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRBs of the Federal University of Juiz de Fora, Brazil and Indiana University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced are available online at https://github.com/TranLab/Brazil-Pv-IgG-Kinetics-2022/.
